SHARE:  
Immunovant to Announce New Indications for Batoclimab

Hosted by Immunovant, Inc. (NASDAQ: IMVT)

Wednesday September 7, 2022
8:00 AM ET
Immunovant to host an investor webcast to announce two new indications for their investigational product candidate, batoclimab (IMVT-1401). The event will feature prepared remarks by company management and external key opinion leaders in the autoimmune disease space.

Batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn).
 
A live question and answer session with Immunovant management will follow.
REGISTRATION INFORMATION
Please register through the link below to attend the event and live Q&A session. An archived recording of the webcast will be available on Immunovant’s website for a limited time following its conclusion, which can be accessed by clicking here.
Register and Attend
250 West 55th Street, Suite 3401 
New York, NY 10019 
Copyright © 2022 LifeSci Advisors, LLC, All rights reserved.
If you are not the named addressee you should not disseminate, distribute or copy this e-mail. Please notify the sender immediately by e-mail if you have received this email by mistake and delete this email from your system. All market prices, data and other information contained in this email are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect the views of LifeSci Advisors, LLC, its affiliates, subsidiaries or agents. The message is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Before opening any attachments please check them for viruses and defects.